Your session is about to expire
← Back to Search
Double Voiding for Urinary Tract Infection Prevention Post-Kidney Transplant
N/A
Recruiting
Led By Muthukumar Thangamani, M.D.
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 3 months of transplantation
Awards & highlights
No Placebo-Only Group
Summary
This trial will assess if "double voiding" reduces UTI risk for kidney transplant recipients, lowering the risk of infection and rejection of the organ.
Who is the study for?
This trial is for adult kidney transplant recipients who are being routinely followed at the NYP-WCM Transplant Clinic. It's not for those discharged with an indwelling catheter (Foley) after their transplant.
What is being tested?
The study compares 'double voiding'—a technique to empty the bladder more completely—with regular voiding to see if it reduces urinary tract infections in new kidney transplant patients.
What are the potential side effects?
There are no direct side effects from participating in this trial as it involves non-invasive techniques of urination, but UTIs themselves can cause discomfort, fever, and may require antibiotics.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ first 3 months of transplantation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 3 months of transplantation
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of UTI's
Secondary study objectives
Time to first bacterial culture
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Double VoidingExperimental Treatment1 Intervention
The participant will be instructed to void twice.
Group II: Regular VoidingActive Control1 Intervention
The participant will be instructed to void normally.
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,091 Previous Clinical Trials
1,154,308 Total Patients Enrolled
Muthukumar Thangamani, M.D.Principal InvestigatorWeill Medical College of Cornell University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You recently had a kidney transplant and still have a catheter in place.All adults who have had a kidney transplant and are regularly seen at the New York Presbyterian - Weill Cornell Medicine Transplant Clinic.
Research Study Groups:
This trial has the following groups:- Group 1: Double Voiding
- Group 2: Regular Voiding
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.